| Literature DB >> 29171692 |
Matthew L Dennis1,2, Michael D Lee1,2, Jitendra R Harjani1, Mohamed Ahmed1,3, Aaron J DeBono1, Noel P Pitcher1, Zhong-Chang Wang1,4, Sandeep Chhabra1, Nicholas Barlow1, Raphaël Rahmani1, Ben Cleary1, Olan Dolezal2, Meghan Hattarki2, Luigi Aurelio1, Jeremy Shonberg1, Bim Graham1, Thomas S Peat2, Jonathan B Baell1,5, James D Swarbrick1.
Abstract
Dihydropteroate synthase (DHPS) is an enzyme of the folate biosynthesis pathway, which catalyzes the formation of 7,8-dihydropteroate (DHPt) from 6-hydroxymethyl-7,8-dihydropterin pyrophosphate (DHPPP) and para-aminobenzoic acid (pABA). DHPS is the long-standing target of the sulfonamide class of antibiotics that compete with pABA. In the wake of sulfa drug resistance, targeting the structurally rigid (and more conserved) pterin site has been proposed as an alternate strategy to inhibit DHPS in wild-type and sulfa drug resistant strains. Following the work on developing pterin-site inhibitors of the adjacent enzyme 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK), we now present derivatives of 8-mercaptoguanine, a fragment that binds weakly within both enzymes, and quantify sub-μm binding using surface plasmon resonance (SPR) to Escherichia coli DHPS (EcDHPS). Eleven ligand-bound EcDHPS crystal structures delineate the structure-activity relationship observed providing a structural framework for the rational development of novel, substrate-envelope-compliant DHPS inhibitors.Entities:
Keywords: DHPS; antibiotics; drug discovery; inhibitors; pterin; substrate-envelope hypothesis
Mesh:
Substances:
Year: 2018 PMID: 29171692 DOI: 10.1002/chem.201704730
Source DB: PubMed Journal: Chemistry ISSN: 0947-6539 Impact factor: 5.236